您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Isolongifolene
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Isolongifolene
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Isolongifolene图片
CAS NO:1135-66-6
包装与价格:
包装价格(元)
5mg电议
10mg电议

产品介绍
Isolongifolene((-)-Isolongifolene)是一种从Murrayakoenigii中分离的三环倍半萜烯。Isolongifolene通过调节P13K/AKT/GSK-3β信号通路来减轻鱼藤酮诱导的氧化应激,线粒体功能障碍和细胞凋亡。Isolongifolene具有抗氧化,抗炎,抗癌和神经保护的特性。
Cas No.1135-66-6
别名异长叶烯; (-)-Isolongifolene
Canonical SMILESCC1(C)[C@]23CC[C@](C3)([H])C(C)(C)C2=CCC1
分子式C15H24
分子量204.35
溶解度DMSO: 10 mg/mL (48.94 mM); Water:< 0.1 mg/mL (insoluble)
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Isolongifolene ((-)-Isolongifolene) is a tricyclic sesquiterpene isolated from Murraya koenigii. Isolongifolene attenuates Rotenone-induced oxidative stress, mitochondrial dysfunction and apoptosis through the regulation of P13K/AKT/GSK-3β signaling pathways. Isolongifolene has antioxidant, anti-inflammatory, anticancer and neuroprotective properties[1].

Isolongifolene (0-50 μM; 26 hours; SH-SY5Y neuroblastoma cells) treatment significantly alleviates Rotenone-induced cytotoxicity in SH-SY5Y cells in a dose-dependent manner[1].Isolongifolene (10 μM; 26 hours; SH-SY5Y neuroblastoma cells) treatment attenuates Rotenone-induced apoptosis in SH-SY5Y cells[1].Isolongifolene (10 μM; 26 hours; SH-SY5Y neuroblastoma cells) treatment attenuates Rotenone induced toxicity by down-regulating Bax, caspases-3, 6, 8 and 9 expression and up-regulating of Bcl-2 expression. Furthermore regulation of p-P13K, p-AKT and p-GSK-3β expression by Isolongifolene[1]. Cell Viability Assay[1] Cell Line: SH-SY5Y neuroblastoma cells

[1]. Balakrishnan R, et al. Isolongifolene attenuates rotenone-induced mitochondrial dysfunction, oxidative stress and apoptosis. Front Biosci (Schol Ed). 2018 Jan 1;10:248-261.